Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

NCT04521413 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancies

Interventions

DRUG: CFI-402411
DRUG: Pembrolizumab

Sponsor

Treadwell Therapeutics, Inc

Collaborators

[object Object]